Company intelligence / Profile preview
Shulov Innovative Science
Rehovot, Central, Israelsis-shulov.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
Completed Phase II clinical study in Herpes labialis (210 participants) with highly encouraging results demonstrating shortened healing time, rapid pain relief, and good safety profile; ZEP-3 has also completed Phase I studies, was well tolerated, and is in Phase II trials for atopic dermatitis and burns, and Phase I/II for lung inflammation
- Therapeutic areas
- Infectious DiseasesDermatologyPulmonology
- Modalities
- PeptidesSmall moleculeSynthetic peptide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Long-term supply contract with Israeli Ministry of Health for snake venoms and anti-veninNo large pharma or major biotech disclosed
Beyond the preview
Go deeper on Shulov Innovative Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shulov Innovative Science.